Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05184881
Other study ID # R.21.11.1534
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date December 1, 2021
Est. completion date December 30, 2022

Study information

Verified date February 2024
Source Mansoura University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cervical facet joints have been implicated as a source of chronic pain in 54-67 % patients with chronic posterior neck pain.1 Intraarticular injections, medial branch nerve blocks and neurolysis of medial branch nerves have been described in managing chronic neck pain of facet joint origin.2 The evidence for long-term therapeutic benefits of intraarticular injections of facet joints is limited. Medial branch nerve blocks show moderate evidence of long-term benefit with evidence of side effects.3 Paraneuraxial nerve blocks have become very popular clinically, due to their clinical and anatomical characteristics. These techniques are comparable to neuraxial nerve blocks in terms of success rate and analgesic efficacy and may confer many of advantages over neuraxial nerve blocks.4 Retrolaminar blocks are among this family that are near but not within the neuraxis like spinals or epidurals.5 Most reports and studies of retrolaminar blocks have been in the context of anesthesia for truncal surgery and truncal pain syndromes (thoracic and abdominal).6 Postoperative and pain treatment cervical retrolaminar blocks studies are currently sparse.7 The major advantage of this technique is minimizing or even eliminating the risk of pneumothorax. Additionally, the risks of nerve root damage and inadvertent injection into a dural sleeve, an intervertebral foramen, or the epidural or intrathecal spaces should also be decreased.8


Description:

This prospective randomized open comparative study will be conducted in pain clinic, Mansoura University Hospitals. The study will be approved by the Ethics Research Committee of the Faculty of Medicine, Mansoura University and will be carried out in compliance with the Helsinki Declaration. Informed written consent will be signed from every patient participating in this study after full description of all details of every aspect in this study. The study participants were randomly grouped on a scale of 1:1, using a computer-generated list of random numbers. The distribution results were sealed in an opaque envelope and kept by the study administrator. On the day of block, the study manager handed the envelope to the anesthesiologist who will perform the block. Grouping: - Group M: cervical medial branch block will done at the affected dermatomal level using 1 mL of a mixture of 0.5 mL 1% lidocaine and 0.5 mL dexamethasome (8mg/2ml). - Group R: cervical retrolaminar block was done using 5 mL of a mixture of 3 mL 1% lidocaine and 2 mL dexamethasome (8mg/2ml) for each affected dermatomal level.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date December 30, 2022
Est. primary completion date August 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Patients more than 18 years old of both genders with cervical facet joint arthropathy confirmed by magnetic resonance imaging (MRI) and neck manual examination and not responding to conservative treatments - numeric rating scale (NRS) = 4 that ranged from 0 (no pain) to 10 (extreme pain)., - American society of Anesthesiology Physical Status class I and II, - Body mass index ? 30 Exclusion Criteria: - The exclusion criteria are patient refusal - local or systemic sepsis, coagulopathy, - unstable cardiovascular and respiratory diseases, - previous neurological deficits, - history of psychiatric disorders, - history of drug abuse, - distorted local anatomy, - those who were allergic to the used medications .

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Retrolaminar block
2- Cervical retrolaminar block: will be performed on prone-positioned patients. Under fluoroscopic visualization, after identification of the lamina at the desired level, a 25-gauge, 3.5-inch spinal needle was introduced and when the needle tip will be confirmed at the posterior aspect of the cervical lamina corresponding to cervical facet arthropathy level. 5 mL of a mixture of 3 mL 1% lidocaine and 2 mL dexamethasome (8mg/2ml) will be injected.
Medial Branch Block
1- Cervical medial branch block: will be performed on prone-positioned patients using a posterior approach. Under fluoroscopic visualization, after identification of the waists of the articular pillars at the desired levels, each medial branch block was administered with a 25-gauge, 3.5-inch spinal needle. When the place of the needle tip will be confirmed at the mid-point of the waists of articular pillars, 1 ml of the mixture of 0.5 mL 1% lidocaine and 0.5 mL dexamethasome (8mg/2ml) will be injected at each level.

Locations

Country Name City State
Egypt Yahya Wahba Mansoura

Sponsors (1)

Lead Sponsor Collaborator
Mansoura University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Numerical rating score from zero to 10 (where 0 no pain, 10 the worst pain) before injection
Primary Numerical rating score from zero to 10 (where 0 no pain, 10 the worst pain) after 2 weeks from injection
Primary Numerical rating score from zero to 10 (where 0 no pain, 10 the worst pain) after 2 month from block
Primary Numerical rating score from zero to 10 (where 0 no pain, 10 the worst pain) after 3 month from block
Secondary Neck disability index Each of the 10 items scores from 0 to 5. The maximum score is 50. 0 to 4 = no disability, 5 to 14 = mild, 15 to 24 = moderate, 25 to 34 = severe and above 34 = complete. before injection
Secondary Neck disability index Each of the 10 items scores from 0 to 5. The maximum score is 50. 0 to 4 = no disability, 5 to 14 = mild, 15 to 24 = moderate, 25 to 34 = severe and above 34 = complete. after 2 weeks from injection
See also
  Status Clinical Trial Phase
Completed NCT05052112 - Cross-Over Study to Evaluate the Efficacy of E-PR-01 on Activity Induced Joint Pain N/A
Recruiting NCT04285112 - SPRINT: Signature for Pain Recovery IN Teens
Completed NCT04506411 - Turmeric Efficacy for Mobility and Joint Function N/A
Terminated NCT00973141 - A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain Phase 2
Completed NCT04408560 - Evaluation of the Efficacy of a Homeopathic Protocol in Patients With Non-metastatic Breast Cancer N/A
Completed NCT04150211 - Effects of Exten(d) Supplementation on Training Ability in Recreational Runners Phase 2
Completed NCT03209895 - Study to Evaluate the Safety and Efficacy of a Proprietary "Joint Health" Dietary Supplement in Subjects With Joint and Connective Tissue Pain N/A
Withdrawn NCT01612728 - Treatment for Joint Pains Due to Aromatase Inhibitor Therapy in Breast Cancer Phase 2
Completed NCT00691678 - Glucosamine and Chondroitin for Aromatase Inhibitor Induced Joint Symptoms in Women With Breast Cancer Phase 2
Recruiting NCT05212259 - Clinical Study to Evaluate the Effect of Different Doses of UC-II® Supplementation on the Range of Motion & Joint Discomfort in Healthy Subjects N/A
Recruiting NCT04182659 - Long Term Efficacy of Neuronavigation Guided rTMS in Alleviating Gulf War Illness Related Headaches and Pain Symptoms N/A
Terminated NCT04712019 - Evaluating Edema and Range of Motion Using Negative Pressure Therapy vs. Standard Surgical Dressing in Bilateral TKA N/A
Recruiting NCT06074744 - Subsartorial Nerve Block and Femoral Nerve Block in Total Knee Arthroplasty N/A
Recruiting NCT00325845 - Synvisc Injections for Lumbar Facet Joint Pain Phase 3
Terminated NCT04872556 - Evaluation of the Effect of Laser Acupuncture on Taxane Acute Pain Syndrome Patients N/A
Active, not recruiting NCT03865992 - Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease N/A
Recruiting NCT05282992 - NAtive Collagen Type II In Healthy VoluntEers With Joint Discomfort N/A
Recruiting NCT04994249 - Diagnostic and Prognostic Biomarkers for High-impact Chronic Pain: Development and Validation
Completed NCT01509079 - Vitamin D3 Effects on Musculoskeletal Symptoms With Use of Aromatase Inhibitors Phase 2
Completed NCT04764110 - Short-term Impact of Cyplexinol® on Self-reported Joint Pain N/A